Scientists at the Johns Hopkins Kimmel Comprehensive Cancer Center and its Bloomberg~Kimmel Institute for Cancer Immunotherapy report that they successfully trained a machine learning algorithm to predict, in hindsight, which patients with melanoma would respond to treatment and which would not respond. The open-source program, DeepTCR, proved valuable as a predictive clinical tool, but it also helped teach the researchers about the biological mechanisms underlying patients’ responses to immunotherapy.